Synergy Innovation Begins Development of Virus Specimen Transport Medium

[Asia Economy Reporter Hyunseok Yoo] Synergy Innovation, the No. 1 domestic company in the culture media market, announced on the 25th that it will begin developing virus specimen transport media.

Specimen transport media are used to preserve specimens collected from patients for virus (including COVID-19 virus) diagnostic tests, preventing deterioration during transportation to testing institutions. The quality of the product, including sterilization to ensure virus survival for a certain period, is important.

Since Synergy Innovation has supplied microbial culture media to global pharmaceutical companies both domestically and internationally, it plans to complete the development and mass production of transport media by the second quarter of this year based on its internationally recognized technological capabilities.

The domestic transport media market suffers from low trust in quality due to manual production and high concerns about stable supply. Synergy Innovation plans to actively respond to global demand by securing uniform quality through an automated system applied in a GMP-certified facility approved by the Ministry of Food and Drug Safety, with a production capacity of up to 3 million units per month.

A company representative stated, “We started development to align with the government’s recent policy to prevent the spread of infectious diseases, and we plan to expand into microbial clinical specimen transport media in the future.” He added, “In a situation where global concerns about infectious diseases are increasing, Synergy Innovation will do its best to contribute to overcoming infectious diseases through stable product supply as the No. 1 company in the culture media market.”

This content was produced with the assistance of AI translation services.